Etay Ziv1, Hooman Yarmohammadi2, F Edward Boas2, Elena Nadia Petre2, Karen T Brown2, Stephen B Solomon2, David Solit3, Diane Reidy4, Joseph P Erinjeri2. 1. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Howard-118, 1275 York Ave., New York, NY10065. Electronic address: etay.ziv@gmail.com. 2. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Howard-118, 1275 York Ave., New York, NY10065. 3. Human Oncology and Pathogenesis Program, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard-118, 1275 York Ave., New York, NY10065. 4. Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard-118, 1275 York Ave., New York, NY10065.
Abstract
PURPOSE: To identify gene mutations in tumors undergoing transarterial embolization and explore the relationship between gene mutations and tumor response to embolization. MATERIALS AND METHODS: This was a retrospective review that included 17 patients with primary or metastatic liver tumors treated with embolization and had specimens analyzed for a 341-gene panel next-generation sequence assay. Pathologic conditions included hepatocellular, carcinoid, pancreatic neuroendocrine, melanoma, medullary thyroid, and liver acinar-cell carcinoma. Disease, procedure data, and tumor response data were collected. Dimensionality reduction was performed by using principal component analysis. A linear support vector machine was used to learn a prediction rule and identify the genes most predictive of objective tumor response (partial or complete) per modified Response Evaluation Criteria In Solid Tumors. Cross-validation was used to test the prediction on the holdout set. Permutation testing was used to determine statistical significance of prediction accuracy. Recursive feature elimination was used to identify the most predictive genes. RESULTS: At 4 months after embolization, 9 tumors showed a response and 8 did not. Using the top two principal components, prediction accuracy of the gene mutation signature was 70% (±11%), which was statistically significant (P < .05). The most predictive genes were CTNNB1, MEN1, and NCOR1: three genes associated with the Wnt/β-catenin and hypoxia signaling pathways. CONCLUSIONS: This study identifies gene mutations in tumors treated with transarterial embolization. A gene-mutation signature obtained from the mutation data suggests that upregulation of the Wnt/β-catenin signaling pathway may be associated with sensitivity to embolization.
PURPOSE: To identify gene mutations in tumors undergoing transarterial embolization and explore the relationship between gene mutations and tumor response to embolization. MATERIALS AND METHODS: This was a retrospective review that included 17 patients with primary or metastatic liver tumors treated with embolization and had specimens analyzed for a 341-gene panel next-generation sequence assay. Pathologic conditions included hepatocellular, carcinoid, pancreatic neuroendocrine, melanoma, medullary thyroid, and liver acinar-cell carcinoma. Disease, procedure data, and tumor response data were collected. Dimensionality reduction was performed by using principal component analysis. A linear support vector machine was used to learn a prediction rule and identify the genes most predictive of objective tumor response (partial or complete) per modified Response Evaluation Criteria In Solid Tumors. Cross-validation was used to test the prediction on the holdout set. Permutation testing was used to determine statistical significance of prediction accuracy. Recursive feature elimination was used to identify the most predictive genes. RESULTS: At 4 months after embolization, 9 tumors showed a response and 8 did not. Using the top two principal components, prediction accuracy of the gene mutation signature was 70% (±11%), which was statistically significant (P < .05). The most predictive genes were CTNNB1, MEN1, and NCOR1: three genes associated with the Wnt/β-catenin and hypoxia signaling pathways. CONCLUSIONS: This study identifies gene mutations in tumors treated with transarterial embolization. A gene-mutation signature obtained from the mutation data suggests that upregulation of the Wnt/β-catenin signaling pathway may be associated with sensitivity to embolization.
Authors: Gao Chen; Jingbo A; Min Wang; Steven Farley; Lung-Yi Lee; Lung-Ching Lee; Mark P Sawicki Journal: Mol Cancer Res Date: 2008-12 Impact factor: 5.852
Authors: Ahsun Riaz; Robert K Ryu; Laura M Kulik; Mary F Mulcahy; Robert J Lewandowski; Jeet Minocha; Saad M Ibrahim; Kent T Sato; Talia Baker; Frank H Miller; Steven Newman; Reed Omary; Michael Abecassis; Al B Benson; Riad Salem Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Etay Ziv; Yiru Zhang; Luke Kelly; Ines Nikolovski; F Edward Boas; Joseph P Erinjeri; Liqun Cai; Elena N Petre; Lynn A Brody; Anne M Covey; George Getrajdman; James J Harding; Constantinos Sofocleous; Ghassan K Abou-Alfa; Stephen B Solomon; Karen T Brown; Hooman Yarmohammadi Journal: Radiology Date: 2020-08-11 Impact factor: 11.105
Authors: Ahmed M Khalaf; David Fuentes; Ali I Morshid; Mata R Burke; Ahmed O Kaseb; Manal Hassan; John D Hazle; Khaled M Elsayes Journal: J Hepatocell Carcinoma Date: 2018-06-27